Sign in

    Salem [Unknown Last Name]Barclays

    Salem [Unknown Last Name]'s questions to Sotera Health Co (SHC) leadership

    Salem [Unknown Last Name]'s questions to Sotera Health Co (SHC) leadership • Q3 2024

    Question

    An analyst from Barclays, on behalf of Luke Sergott, inquired about Sterigenics' performance, seeking more detail on customer destocking visibility. They also asked for an update on the timelines for the Georgia litigation cases and the number of claimants in California.

    Answer

    CEO Michael Petras acknowledged that while bioprocessing is a small part of the business, it saw sequential growth but remains down year-over-year. He stated that overall volumes in Sterigenics are improving as expected. On litigation, Petras confirmed the number of California claimants is stable at 18 and expects a ruling on the Phase I general causation hearings for the Georgia cases by late January 2025.

    Ask Fintool Equity Research AI